Alignment Healthcare (ALHC) Projected to Post Quarterly Earnings on Thursday

Alignment Healthcare (NASDAQ:ALHC) is expected to post its Q4 2025 results after the market closes on Thursday, February 26th. Analysts expect Alignment Healthcare to post earnings of ($0.15) per share and revenue of $1.0034 billion for the quarter. Parties may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Thursday, February 26, 2026 at 5:00 PM ET.

Alignment Healthcare Stock Down 0.4%

Shares of NASDAQ ALHC opened at $20.51 on Thursday. The stock has a market cap of $4.10 billion, a P/E ratio of -170.92, a PEG ratio of 5.25 and a beta of 1.16. The business’s fifty day simple moving average is $20.98 and its 200-day simple moving average is $18.25. Alignment Healthcare has a 12-month low of $11.63 and a 12-month high of $23.87. The company has a current ratio of 1.61, a quick ratio of 1.61 and a debt-to-equity ratio of 1.99.

Insider Transactions at Alignment Healthcare

In other news, insider Christopher J. Joyce sold 10,611 shares of the business’s stock in a transaction dated Friday, January 2nd. The stock was sold at an average price of $20.03, for a total value of $212,538.33. Following the completion of the sale, the insider directly owned 297,088 shares of the company’s stock, valued at approximately $5,950,672.64. The trade was a 3.45% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, President Dawn Christine Maroney sold 30,000 shares of the company’s stock in a transaction dated Tuesday, February 17th. The shares were sold at an average price of $20.63, for a total value of $618,900.00. Following the completion of the sale, the president directly owned 997,015 shares of the company’s stock, valued at approximately $20,568,419.45. This trade represents a 2.92% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 2,150,938 shares of company stock valued at $42,274,570 over the last quarter. 7.00% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Alignment Healthcare

A number of hedge funds have recently modified their holdings of the business. Wellington Management Group LLP raised its position in Alignment Healthcare by 167.3% in the 3rd quarter. Wellington Management Group LLP now owns 11,089,727 shares of the company’s stock valued at $193,516,000 after purchasing an additional 6,940,277 shares during the last quarter. Invesco Ltd. increased its stake in Alignment Healthcare by 122.3% in the second quarter. Invesco Ltd. now owns 4,170,529 shares of the company’s stock valued at $58,387,000 after purchasing an additional 2,294,739 shares during the period. Loomis Sayles & Co. L P purchased a new stake in shares of Alignment Healthcare in the fourth quarter valued at about $44,162,000. Qube Research & Technologies Ltd raised its stake in Alignment Healthcare by 269.6% during the 2nd quarter. Qube Research & Technologies Ltd now owns 1,523,986 shares of the company’s stock valued at $21,336,000 after acquiring an additional 1,111,685 shares during the last quarter. Finally, Bank of America Corp DE lifted its position in Alignment Healthcare by 273.5% during the 3rd quarter. Bank of America Corp DE now owns 1,412,498 shares of the company’s stock worth $24,648,000 after acquiring an additional 1,034,273 shares during the period. 86.19% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities analysts have recently issued reports on ALHC shares. Wall Street Zen upgraded Alignment Healthcare from a “hold” rating to a “buy” rating in a research note on Saturday, February 7th. The Goldman Sachs Group reiterated a “buy” rating and issued a $22.00 price target on shares of Alignment Healthcare in a research note on Monday, November 3rd. Zacks Research downgraded shares of Alignment Healthcare from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, October 28th. Robert W. Baird set a $28.00 price objective on shares of Alignment Healthcare in a report on Friday, January 30th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Alignment Healthcare in a research note on Wednesday, January 21st. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Alignment Healthcare presently has an average rating of “Moderate Buy” and an average target price of $23.32.

Alignment Healthcare Company Profile

Alignment Healthcare, Inc (NASDAQ: ALHC) is a health care company specializing in value-based care for Medicare Advantage beneficiaries. The company leverages an integrated care model that combines in-home clinical services, telehealth capabilities and digital health tools to manage chronic conditions, improve outcomes and enhance patient experience.

At the core of Alignment Healthcare’s approach is a proprietary technology platform that aggregates real-time clinical and claims data to support preventive care, risk stratification and personalized care plans.